MX2018006960A - Composiciones que comprenden epicatequina 3'-o-glucuronido y metodos para preparar y usar esas composiciones. - Google Patents
Composiciones que comprenden epicatequina 3'-o-glucuronido y metodos para preparar y usar esas composiciones.Info
- Publication number
- MX2018006960A MX2018006960A MX2018006960A MX2018006960A MX2018006960A MX 2018006960 A MX2018006960 A MX 2018006960A MX 2018006960 A MX2018006960 A MX 2018006960A MX 2018006960 A MX2018006960 A MX 2018006960A MX 2018006960 A MX2018006960 A MX 2018006960A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- compositions
- 3gec
- overweight
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Las composiciones pueden comprender el metabolito de flavanol epicatequina 3'-O-glucurónido (3GEC). En algunas modalidades, la cantidad de 3GEC es eficaz para aumentar el gasto de energía, la actividad del sistema nervioso simpático y/o la oxidación de grasas. Dicha composición puede usarse en un método para respaldar el control del peso o promover la pérdida de peso, un método para prevenir la obesidad o el sobrepeso y un método para tratar la obesidad o el sobrepeso. En algunas modalidades, la composición puede mejorar la sensibilidad a la insulina, la tolerancia a la glucosa, el rendimiento cognitivo, la cognición, el estado de ánimo y/o la memoria. En algunas modalidades, la composición puede lograr un efecto terapéutico seleccionado del grupo que consiste en dilatar los vasos sanguíneos, reducir la tensión arterial, aumentar el suministro de flujo sanguíneo a los tejidos en el cuerpo, mejorar la circulación sanguínea, por ejemplo, en el cerebro, estimular la síntesis de proteínas, aumentar la liberación de factores de crecimiento, mejorar la función inmunitaria, y combinaciones de estos. En algunas modalidades, la composición puede tratar o prevenir la disfagia, por ejemplo, al provocar el reflejo de la deglución.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268035P | 2015-12-16 | 2015-12-16 | |
| US201662286728P | 2016-01-25 | 2016-01-25 | |
| PCT/EP2016/081225 WO2017102965A1 (en) | 2015-12-16 | 2016-12-15 | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006960A true MX2018006960A (es) | 2018-09-05 |
Family
ID=57570255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006960A MX2018006960A (es) | 2015-12-16 | 2016-12-15 | Composiciones que comprenden epicatequina 3'-o-glucuronido y metodos para preparar y usar esas composiciones. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200261485A1 (es) |
| EP (1) | EP3389666A1 (es) |
| JP (1) | JP2019505484A (es) |
| CN (1) | CN108367015A (es) |
| AU (1) | AU2016374453A1 (es) |
| BR (1) | BR112018011463A2 (es) |
| CA (1) | CA3008354A1 (es) |
| MX (1) | MX2018006960A (es) |
| WO (1) | WO2017102965A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021193703A1 (ja) * | 2020-03-24 | 2021-09-30 | 学校法人 芝浦工業大学 | 中枢神経賦活組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2557079A1 (en) * | 2011-08-09 | 2013-02-13 | Nestec S.A. | Synthesis of catechin and epicatechin conjugates |
-
2016
- 2016-12-15 EP EP16812939.3A patent/EP3389666A1/en not_active Withdrawn
- 2016-12-15 CN CN201680073420.XA patent/CN108367015A/zh active Pending
- 2016-12-15 US US16/061,527 patent/US20200261485A1/en not_active Abandoned
- 2016-12-15 BR BR112018011463A patent/BR112018011463A2/pt not_active Application Discontinuation
- 2016-12-15 AU AU2016374453A patent/AU2016374453A1/en not_active Abandoned
- 2016-12-15 JP JP2018530052A patent/JP2019505484A/ja not_active Withdrawn
- 2016-12-15 WO PCT/EP2016/081225 patent/WO2017102965A1/en active Application Filing
- 2016-12-15 MX MX2018006960A patent/MX2018006960A/es unknown
- 2016-12-15 CA CA3008354A patent/CA3008354A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200261485A1 (en) | 2020-08-20 |
| AU2016374453A1 (en) | 2018-05-31 |
| CN108367015A (zh) | 2018-08-03 |
| EP3389666A1 (en) | 2018-10-24 |
| WO2017102965A1 (en) | 2017-06-22 |
| CA3008354A1 (en) | 2017-06-22 |
| JP2019505484A (ja) | 2019-02-28 |
| BR112018011463A2 (pt) | 2018-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500169A1 (en) | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders | |
| MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
| AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
| BR112017020132A2 (pt) | métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição | |
| RU2012156850A (ru) | Предварительно сгущенная компактная жидкая питательная композиция для пациентов с дисфагией | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| AR082411A1 (es) | siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO | |
| RU2013121737A (ru) | Экстракты кофе в качестве ингредиентов пищевых продуктов, лекарств, косметических средств, пищевых добавок и биопрепаратов | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MX2017017136A (es) | Composicion para el tratamiento de la nafld. | |
| Shree et al. | Can yoga therapy stimulate stem cell trafficking from bone marrow? | |
| MX2018006960A (es) | Composiciones que comprenden epicatequina 3'-o-glucuronido y metodos para preparar y usar esas composiciones. | |
| EA201401155A1 (ru) | Препарат и способ профилактики и лечения атипичного остеопороза | |
| BR112017023493A2 (pt) | composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições | |
| WO2016008642A3 (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| Alves et al. | Insular cortex α1-adrenoceptors modulate the parasympathetic component of the baroreflex in unanesthetized rats | |
| EA201500137A1 (ru) | Способ лечения аддикции | |
| de Vos | Spinal cord stimulation and modulation of neuropathic pain | |
| Mishima et al. | Transcranial direct current stimulation alters microglial morphology in mice | |
| Katz et al. | Individual differences in tDCS augmented working memory training | |
| PL431538A1 (pl) | Preparat zawierający ekstrakt z Tamarindus indica modulujący ekspresję mRNA i miRNA, sposób regulacji zaburzeń rytmów biologicznych w skórze oraz zastosowanie ekstraktu z Tamrindus indica | |
| PL431537A1 (pl) | Preparat zawierający ekstrakt z nasion Punica granatum zwiększający ekspresję genu BMAL1 i obniżający ekspresję genu PER1, sposób regulacji zaburzeń rytmów biologicznych w skórze oraz zastosowanie ekstraktu z nasion Punica granatum | |
| Cazzato et al. | Off-line rTMS of left Dorsolateral Prefrontal Cortex reduces food cravings in females but not males | |
| CN104087678B (zh) | Vinexin-β在治疗脑卒中疾病中的应用 | |
| PL431536A1 (pl) | Preparat zawierający ekstrakt z owoców Citrus bergamia obniżający ekspresję genu PER1, sposób regulacji zaburzeń rytmów biologicznych w skórze oraz zastosowanie ekstraktu z owoców Citrus bergamia |